Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Advanced Cell Technology, Inc. (“ACT”;OTCQB: ACTC), a leader in the field of regenerative medicine, announced today second quarter financial results for the period ended June 30, 2013.
•Confirmed that a clinical trial participant showed improvement in vision from 20/400 to 20/40 following treatment with retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs), which was first reported in a news article on May 15 by Reuters
Hey, check out all the research scientist jobs. Post your resume today!
